Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data
Medical Sciences · 13.11.2026 · 14 (7) · 778
DOI: 10.3390/medsci14070778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 13.11.2026. Verfasst von Yijun Shao und 10 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute on Aging, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Objectives
Alzheimer’s disease and related dementias (ADRD) impose substantial clinical and public health burdens, while treatment options remain limited. We developed a novel mechanism-agnostic Medication-Wide Association Study (MWAS) approach to identify medications associated with ADRD using longitudinal electronic health records and explainable artificial intelligence (AI).
Methods
Veterans Health Administration data from 1999–2022 were used to assemble 505,817 matched case–control pairs (1,011,634 Veterans). Cases were defined by ADRD-related diagnosis codes or ADRD-related medication prescriptions, and controls were free of ADRD diagnosis and ADRD-related medication use. Historical features were aggregated into annual intervals ending 1 year before the index date. An upgraded Hybrid Value-Aware Transformer (HVAT 2.0) jointly modeled longitudinal and nonlongitudinal data, including cumulative medication dose. To enhance interpretability, we applied a medication-specific impact score method to estimate model-derived associations between medication exposure and ADRD risk.
Results
The model demonstrated stable performance across data partitions, with area under the receiver operating characteristic curve values of 0.791 in the training set, 0.772 in the validation set, and 0.775 in the testing set. Metolazone and varenicline had the most negative population-level impact scores: −0.196 per 1800 mg and −0.134 per 280 mg cumulative dose unit, respectively, suggesting potentially protective associations with new-onset ADRD. Although individual-level impact scores varied, most exposed patients had negative scores, including 12,020 of 12,480 metolazone users (96%) and 8341 of 8786 varenicline users (95%).
Conclusions
MWAS combining dose-aware longitudinal modeling and explainable AI can generate medication-repurposing signals from population-scale real-world data. The hypotheses generated require further epidemiologic and clinical validation.
Förderung
- National Institute on Aging
- U.S. Department of Veterans Affairs
Zitieren
APA
Shao, Y., Yin, Y., Cheng, Y., McGeary, J. E., Taveira, T. H., Tsuang, D. W., Logue, M. W., Ayandeh, S., Ahmed, A., Zamrini, E., & Zeng-Treitler, Q. (2026). Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data. Medical Sciences, 14(7), 778. https://doi.org/10.3390/medsci14070778
Vancouver
Shao Y, Yin Y, Cheng Y, McGeary JE, Taveira TH, Tsuang DW, et al. Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data. Medical Sciences. 2026;14(7):778. doi:10.3390/medsci14070778
BibTeX
@article{Shao2026,
author = {Shao, Yijun and Yin, Ying and Cheng, Yan and McGeary, John E. and Taveira, Tracey H. and Tsuang, Debby W. and Logue, Mark W. and Ayandeh, Siamack and Ahmed, Ali and Zamrini, Edward and Zeng-Treitler, Qing},
title = {Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {7},
pages = {778},
doi = {10.3390/medsci14070778}
}
EUVIMED